<table>
<thead>
<tr>
<th>Title</th>
<th>Male breast cancer in BRCA1 and BRCA1 mutation carriers: pathology data from the consortium of investigators of Modifiers of BRCA1/2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Silvestri, V; Barrowdale, D; Mulligan, AM; Neuhausen, SL; Fox, S; Karlan, BY; Mitchell, G; James, P; Thull, DL; Kwong, A</td>
</tr>
<tr>
<td>Citation</td>
<td>Breast Cancer Research, 2016, v. 18 n. 1, p. 15</td>
</tr>
<tr>
<td>Issued Date</td>
<td>2016</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10722/226428">http://hdl.handle.net/10722/226428</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
RESEARCH ARTICLE

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

Valentina Silvestri$^{11}$, Daniel Barrowdale$^{21}$, Anna Marie Mulligan$^{3,4}$, Susan L. Neuhausen$^{5}$, Stephen Fox$^{6}$, Beth Y. Karlan$^{7}$, Gillian Mitchell$^{8,9}$, Paul James$^{8,9}$, Darcy L. Thull$^{10}$, Kristin K. Zorn$^{10}$, Natalie J. Carter$^{11}$, Katherine L. Nathanson$^{12}$, Susan M. Domchek$^{12}$, Timothy R. Rebbeck$^{13}$, Susan J. Ramsu$^{14}$, Robert L. Nussbaum$^{15}$, Olufunmilayo I. Olopade$^{16}$, Johanna Rantala$^{17}$, Sook-Yee Yoon$^{18,19}$, Maria A. Caligo$^{20}$, Laura Spugnesi$^{20}$, Anders Bojesen$^{21}$, Inge Sokilde Pedersen$^{22}$, Mads Thomassen$^{23}$, Uffe Birk Jensen$^{24}$, Amanda Ewart Toland$^{25}$, Leigha Senter$^{26}$, Irene L. Andrulis$^{4,27,28}$, Gord Glendon$^{27}$, Peter J. Hulick$^{29}$, Evgeny N. Imyanitov$^{30}$, Mark H. Greene$^{31}$, Phuong L. Mai$^{31}$, Christian F. Singer$^{32}$, Christine Rappaport-Fuerhauer$^{32}$, Gero Kramer$^{33}$, Joseph Vijai$^{34}$, Kenneth Offit$^{34}$, Mark Robson$^{35}$, Anne Lincoln$^{34}$, Lauren Jacobs$^{34}$, Eva Machackova$^{36}$, Lenka Foretova$^{37}$, Marie Navratilova$^{36}$, Petra Vaisickova$^{36}$, Fergus J. Couch$^{38,39}$, Emily Hallberg$^{39}$, Kathryn J. Ruddy$^{40}$, Priyanka Sharma$^{41}$, Sung-Won Kim$^{42}$, iConFab Investigators, Manuel R. Teixeira$^{43,44}$, Pedro Pinto$^{43}$, Marco Montagna$^{45}$, Laura Matricardi$^{45}$, Adalgeir Arason$^{46}$, Oskar Th Johannsson$^{47}$, Rosa B. Barkardottir$^{48}$, Anna Jakubowska$^{49}$, Jan Lubinski$^{49}$, Angel Izquierdo$^{49}$, Miguel Angel Pujana$^{50}$, Judith Balmaña$^{51}$, Orland Diez$^{52}$, Gabriella Ivach$^{53}$, Janos Papp$^{54}$, Edith Olah$^{54}$, Ava Kwong$^{55,56}$, Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Heli Nevanlinna$^{57}$, Kristiina Aittomäki$^{58}$, Pedro Perez Segura$^{59}$, Trinidad Caldes$^{60}$, Tom Van Maerken$^{61}$, Bruce Poppe$^{61}$, Kathleen B. M. Clae$^{61}$, Claudine Isaacs$^{62}$, Camille Elan$^{63}$, Christine Lasset$^{64,65}$, Dominique Stoppa-Lyonnet$^{66,67}$, Laure Barjhoux$^{67}$, Muriel Belotti$^{63}$, Alfons Meind$^{68}$, Andrea Gehrig$^{69}$, Christian Sutter$^{70}$, Christoph Engel$^{71}$, Dieter Niederacher$^{72}$, Doris Steinemann$^{73}$, Eric Hahnne$^{74}$, Karin Kast$^{75}$, Norbert Arnold$^{76}$, Raymonda Varon-Mateeva$^{77,78}$, Dorothea Wandel$^{79}$, Andrew K. Godwin$^{79}$, D. Gareth Evans$^{80}$, Debra Frost$^{80}$, Jo Perkins$^{80}$, Julian Adlard$^{81}$, Louise Izatt$^{82}$, Radka Platte$^{83}$, Ros Eeles$^{84}$, Steve Ellis$^{2}$, EM-BRACE, Ute Hamann$^{84}$, Judy Pinto$^{85}$, Florentia Fostira$^{86}$, George Fountzilas$^{87}$, Barbara Pasini$^{88,89}$, Giuseppe Giannini$^{1}$, Piera Rizzolo$^{1}$, Antonio Russo$^{90}$, Laura Cortesi$^{91}$, Laura Papi$^{92}$, Liliana Varesco$^{93}$, Domenico Palli$^{94}$, Ines Zanna$^{94}$, Antonella Savarese$^{95}$, Paolo Radice$^{96}$, Siranouh Manoukian$^{97}$, Bernard Peissel$^{97}$, Monica Barile$^{98}$, Bernardo Bonanni$^{98}$, Alessandra Vie1$^{99}$, Valeria Pensotti$^{100,101}$, Stefania Tommasi$^{102}$, Paolo Peterlongo$^{100}$, Jeffrey N. Weitzel$^{103}$, Ana Osorio$^{104,105}$, Javier Benitez$^{105,106,107}$, Lesley McGuffog$^{2}$, Sue Healey$^{108}$, Anne-Marie Gerdes$^{109}$, Bent Ejlersen$^{110}$, Thomas V. O. Hansen$^{111}$, Linda Steele$^{5}$, Yuan Chun Ding$^{9}$, Nadine Tung$^{112}$, Ramunas Janavicius$^{113}$, David E. Goldgar$^{114}$, Saundra S. Buys$^{115}$, Mary B. Daly$^{116}$, Anita Bane$^{117}$, Mary Beth Terry$^{118}$, Esther M. John$^{119}$, Melissa Southey$^{118}$, Douglas F. Easton$^{2}$, Georgia Chenevix-Trench$^{108}$, Antonis C. Antoniou$^{2}$ and Laura Ottini$^{14,14}$

* Correspondence: laura.ottini@uniroma1.it
Equal contributors
$^{1}$Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy
Full list of author information is available at the end of the article

© 2016 Silvestri et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Abstract

Background: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).

Methods: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.

Results: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis ($P = 0.005$). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage ($P$ for trend $= 2 \times 10^{-5}$) and higher grade ($P$ for trend $= 0.005$) and were more likely to be oestrogen receptor–positive [odds ratio (OR) 10.59; 95% confidence interval (CI) 5.15–21.80] and progesterone receptor–positive (OR 5.04; 95% CI 3.17–8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database ($P$ for trend $= 4 \times 10^{-12}$).

Conclusions: On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.

Keywords: Male breast cancer, BRCA1/2, Pathology, Histologic grade, Genotype–phenotype correlations

Background

Male breast cancer (MBC) is a rare disease. It accounts for less than 1% of all breast cancers and less than 1% of all cancers in men. The annual incidence is estimated at about 1 per 100,000 men worldwide [1], and lifetime risk is less than 1 in 1000. Incidence rates for MBC increase linearly and steadily with age, with the mean age at diagnosis being between 60 and 70 years [2]. Family history of breast cancer is an important risk factor for developing MBC, suggesting the importance of genetic factors in MBC susceptibility [3, 4]. Mutations in the two major high-penetrance breast cancer genes, BRCA1 (breast cancer 1, early onset gene) and predominantly BRCA2 (breast cancer 2, early onset gene), account for approximately 10% of MBCs outside populations with BRCA founder mutations [5]. The lifetime risk of developing MBC has been estimated to be in the range of 1–5% for BRCA1 and 5–10% for BRCA2 mutation carriers, compared with a risk of 0.1% in the general population [6–9].

MBC is recognised as being a hormone-dependent malignancy, and it is widely accepted as an oestrogen-driven disease, specifically related to hyperestrogenism [10]. In the general population, MBC is similar to late-onset, post-menopausal, oestrogen receptor–/progesterone receptor–positive (ER+/PR+) female breast cancer (FBC). However, compared with FBC, MBC has been reported to occur later in life, present at a higher stage and display lower histologic grade, with a higher proportion of ER+ and PR+ tumours [11].

There is increasing evidence suggesting that MBC may be a group of molecularly and clinically heterogeneous malignancies which differ from those seen in women [12]. It is well known that breast cancer in women is a heterogeneous disease. Breast cancers arising in female BRCA1 mutation carriers display characteristic pathologic features, including distinct morphology (i.e., carcinomas with medullary features) and a triple-negative phenotype [i.e., ER−, PR−, human epidermal growth factor receptor 2− (HER2−)] in the majority. In contrast, BRCA2 breast tumours are a more heterogeneous group, being broadly similar to non-BRCA–associated breast tumours, which more closely resemble post-menopausal FBCs, although with a tendency to be of high grade and HER2− [13].

Current knowledge of the pathologic characteristics of breast cancers arising in male BRCA1/2 mutation carriers is limited, owing to the small number of carriers included in individual studies [14–17]. In a study including 50 male BRCA1/2 mutation carriers, it was suggested that BRCA2 MBCs may represent a subgroup of tumours with a peculiar phenotype not identified in FBC and characterised by an aggressive biological behaviour [16]. Furthermore, in a study including 28 male BRCA1/2 mutation carriers, a possible BRCA2 phenotype characterised by micropapillary histology was suggested [17]. In other, smaller studies, BRCA2 MBCs were associated with younger age at diagnosis and positive lymph node status [14, 15].
In this study, we report pathology data characteristics of 419 BRCA1/2 MBCs derived from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), who conducted the largest study of its kind to date. The main objective of our study was to characterise the pathologic features of BRCA1/2 MBCs and contrast those with the characteristics of BRCA1/2 FBCs, as well as with MBCs in the general population.

Methods

CIMBA study participants

CIMBA collects data on male and female BRCA1 or BRCA2 pathogenic mutation carriers older than 18 years of age, with the majority recruited through cancer genetics clinics [18]. CIMBA data were submitted by 55 study groups in 24 countries based in Europe, North America and Australia. Pathology data from MBC cases for the present analysis were collected by 35 study groups (Additional file 1). Key variables collected for all CIMBA patients include year of birth, age at cancer diagnosis (breast, ovarian or prostate cancers), age at last observation, family membership, race and/or ethnicity and information on applicable prophylactic surgeries. This work was restricted to male and female mutation carriers who had been diagnosed with breast cancer and were of self-reported European ancestry. The number of male mutation carriers of non-European ancestry (2 BRCA1 and 20 BRCA2) was too small to allow a meaningful analysis. These subjects were excluded from the analysis.

A signed informed consent form was obtained from study participants. All participating studies were approved by local ethical review committees (Additional file 2).

Tumour pathology data

MBC pathology data were obtained from a range of sources, namely medical, pathology or tumour registry records and immunohistochemical staining and/or scoring of tissue microarrays (TMAs) (Additional file 3). The data included information on ER, PR and HER2 status; morphological subtype; lymph node involvement; TNM (tumour, node, metastasis) staging and histologic grade. For ER, PR and HER2, status was classified as negative or positive. The vast majority of centres employed a cut-off of either ≥10 % or ≥1 % of tumour nuclei staining positive to define ER/PR receptor positivity, which was not centrally reclassified, owing to the low proportion of records with supporting staining data (Additional file 3). HER2 status was determined using immunohistochemistry (IHC) to detect strong complete membrane staining (with 3+ considered positive) with in situ hybridisation to detect HER2 gene amplification in equivocal cases. Consistency checks were performed to validate receptor data against supplementary scoring information when provided. Central pathology review was not performed.

Each carcinoma was assigned to a morphologic subgroup (ductal, lobular, medullary, other), which was confirmed using the World Health Organisation International Classification of Diseases 0 code for the classification of tumour type when present. Lymph node status, along with the number of nodes showing metastatic carcinoma, was provided when available. Staging data were based on the AJCC Cancer Staging Manual, Sixth Edition [19], with data provided on overall stage and its major attributes (primary tumour size, regional lymph node involvement and presence of distant metastasis). Histologic grade was determined by local pathologists using modifications of the Scarff-Bloom-Richardson histological grading system as grade 1, 2 or 3. Pathology data for FBCs included in the study are described in detail elsewhere [13].

SEER data

We obtained MBC pathology data from the SEER 18 Registries Database for cases diagnosed from 1973 to 2011 [20]. For this study, we selected only male Caucasian cases diagnosed with invasive breast cancer. For SEER cases, pathology characteristics included age at diagnosis; morphologic subgroup; tumour grade; lymph node status; adjusted stage based on the AJCC Cancer Staging Manual, Sixth Edition [19]; ER, PR and HER2 status. Tumour grade was classified as grade 1 (well differentiated), grade 2 (moderately differentiated) or grade 3 (poorly differentiated).

SEER includes unselected MBCs, most of which are of unknown BRCA1/2 mutation status. On the basis of published data [3, 21, 22], about 10 % of MBC cases are expected to be due to BRCA1 or BRCA2 mutations.

Statistical methods

Logistic regression was used to assess the association between pathologic characteristics and male BRCA1/2 mutation carrier status, as well as to compare pathologic characteristics with data from female BRCA1/2 mutation carriers and from male breast tumours arising in the general population using SEER data. In the logistic regression analysis, each pathologic characteristic was treated as the explanatory variable. The outcome variables were BRCA mutation status (BRCA1/BRCA2), sex (female/male) and carrier status (general population/BRCA1 mutation carrier and general population/BRCA2 mutation carrier), with the first term used as the reference group. For assessment of continuous or ordered variables, such as age at diagnosis, stage and grade, tests for trend were also performed.

Analyses within CIMBA data were adjusted for age at diagnosis and country of origin, whereas comparisons between CIMBA and SEER data were adjusted only for age at diagnosis. In addition, an adjustment for calendar year of diagnosis was included in all analyses, based on
the following groupings: up to 1990, 1991–2000 and after 2000. A robust variance approach was used to allow for dependencies between related individuals. All analyses were carried out using Stata v13 software (StataCorp, College Station, TX, USA).

Results
Pathologic characteristics of MBC in BRCA1 and BRCA2 mutation carriers
Information was available for 419 MBC cases, including 375 BRCA2 and 44 BRCA1 mutation carriers (Additional file 1). Median age at MBC diagnosis was 62 years [inter-quartile range (IQR) 16] for BRCA2 mutation carriers and 62 years (IQR 18) for BRCA1 mutation carriers.

The analysis was restricted to carriers diagnosed with invasive breast cancer (326 BRCA2 and 40 BRCA1) (Additional file 4). The majority of tumours were invasive ductal carcinoma in both BRCA2 (95.1 %) and BRCA1 (100 %) carriers. Among tumours with data on stage and grade, the majority of BRCA2 mutation carriers presented with stage 2 disease (47 %) and tumours of histologic grade 3 (56.7 %), whereas the majority of BRCA1 mutation carriers presented with stage 3–4 disease (42.9 %) and histologic grade 3 tumours (69.2 %). Among tumours with ER, PR and HER2 data, 96.7 % were ER+, 86.8 % were PR+ and 83.4 % were HER2- in BRCA2 mutation carriers, vs. 90.3 % ER+, 78.6 % PR+ and 89.5 % HER2- in BRCA1 mutation carriers.

Age at diagnosis was inversely associated with grade in BRCA2 mutation carriers (grade 1/2 vs. grade 3, P = 0.005), with no evidence for differences in ER, PR and HER2 distributions by age (test for differences P > 0.05 for all) (Fig. 1). Furthermore, there was no evidence of association between grade and ER or PR status (P values for trend = 0.50 and 0.78, respectively). For BRCA1 mutation carriers, no differences in age-specific proportions of tumours by grade or ER, PR and HER2 status were observed, but their numbers were small (data not shown).

When we compared the pathologic characteristics of MBC in BRCA1 and BRCA2 mutation carriers, we observed no statistically significant differences. However, tumours in BRCA1 mutation carriers were more likely to

Fig. 1 Age-specific proportion of BRCA2 (breast cancer 2, early onset gene) male breast cancers according to pathologic characteristics. a Grade. b Oestrogen receptor (ER) status. c Progesterone receptor (PR) status. d Human epidermal growth factor receptor 2 (HER2) status. Error bars represent confidence intervals associated with each proportion.
present with more advanced stage (42.9 % vs. 23.5 %, \( P \) for trend = 0.11) and were more frequently ER− (9.7 % vs. 3.3 %, \( P = 0.17 \)) and PR− (21.4 % vs. 13.2 %, \( P = 0.27 \)) than tumours in BRCA2 mutation carriers (Additional file 4).

**Characterisation of BRCA2 MBCs: comparison with BRCA2 FBC and with MBC in the general population**

We evaluated possible pathologic differences between invasive breast cancers arising in male and female BRCA2 mutation carriers by comparing available data from female mutation carriers with breast cancer in the CIMBA dataset. Data from 3750 country-matched female BRCA2 mutation carriers diagnosed with invasive breast cancer were included in this analysis (Table 1). The results revealed that there were significantly fewer invasive lobular carcinomas among male BRCA2 mutation carriers than among female BRCA2 mutation carriers [odds ratio (OR) 0.14, 95 % confidence interval (CI) 0.05–0.43]. In addition,

| Table 1 | Pathology of invasive BRCA2 female and male breast tumours and ORs in predicting male BRCA2 mutation carrier status |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Females Number | Females Percent | Males Number | Males Percent | Unadjusted OR (95 % CI) | Adjusted ORa (95 % CI) |
| **Total**       | 3750            | 326             |                |                | Reference         | Reference         |
| **Morphology**  |                |                |                |                | Reference         | Reference         |
| Ductal carcinoma| 2693            | 83.6           | 253           | 95.1           | 0.15 (0.06–0.41) | 0.14 (0.05–0.43)  |
| Lobular carcinoma| 276            | 8.6            | 4             | 1.5            | 0.35 (0.09–1.46) | 0.46 (0.10–2.11)  |
| Medullary carcinoma| 60          | 1.9            | 2             | 0.8            | 0.39 (0.18–0.83) | 0.54 (0.24–1.23)  |
| Other           | 193            | 6.0            | 7             | 2.6            | Reference         | Reference         |
| **TNM stage**   |                |                |                |                | Reference         | Reference         |
| 0–1             | 560            | 40.2           | 44            | 29.5           | Reference         | Reference         |
| 2               | 629            | 45.1           | 70            | 47.0           | 1.42 (0.95–2.10) | 1.97 (1.20–3.23)  |
| 3–4             | 205            | 14.7           | 35            | 23.5           | 2.17 (1.37–3.44) | 3.55 (1.96–6.44)  |
| **Histologic grade** |            |                |                |                | Reference         | Reference         |
| Grade 1         | 149            | 5.9            | 8             | 3.5            | Reference         | Reference         |
| Grade 2         | 1057           | 41.7           | 92            | 39.8           | 1.62 (0.77–3.41) | 1.88 (0.76–4.67)  |
| Grade 3         | 1329           | 52.4           | 131           | 56.7           | 1.84 (0.88–3.83) | 2.66 (1.08–6.55)  |
| **Lymph node status** |            |                |                |                | Reference         | Reference         |
| Negative        | 1398           | 52.4           | 123           | 50.2           | Reference         | Reference         |
| Positive        | 1270           | 47.6           | 122           | 49.8           | 1.09 (0.84–1.43) | 1.55 (1.12–2.14)  |
| **ER status**   |                |                |                |                | Reference         | Reference         |
| Negative        | 650            | 22.7           | 8             | 3.3            | Reference         | Reference         |
| Positive        | 2211           | 77.3           | 236           | 96.7           | 8.67 (4.26–17.66) | 10.59 (5.15–21.80) |
| **PR status**   |                |                |                |                | Reference         | Reference         |
| Negative        | 892            | 35.0           | 30            | 13.2           | Reference         | Reference         |
| Positive        | 1654           | 65.0           | 198           | 86.8           | 3.56 (2.41–5.26) | 5.04 (3.17–8.04)  |
| **HER2 status** |                |                |                |                | Reference         | Reference         |
| Negative        | 1404           | 85.9           | 126           | 83.4           | Reference         | Reference         |
| Positive        | 230            | 14.1           | 25            | 16.6           | 1.21 (0.77–1.90) | 1.22 (0.70–2.11)  |
| **Subtypes**    |                |                |                |                | Reference         | Reference         |
| ER+ and/or PR+, HER2− | 1112       | 69.8           | 118           | 81.9           | Reference         | Reference         |
| ER+ and/or PR+, HER2+ | 182       | 11.4           | 22            | 15.3           | 1.14 (0.70–1.84) | 1.18 (0.65–2.13)  |
| ER−, PR−, HER2+ | 40            | 2.5            | 2             | 1.4            | 0.47 (0.11–1.98) | 0.42 (0.09–1.98)  |
| Triple-negative (ER−, PR−, HER2−) | 260 | 16.3 | 2 | 1.4 | 0.07 (0.02–0.30) | 0.05 (0.01–0.22)  |
| ER+ and/or PR+, HER2− vs. others | 51 | 0.33–0.79 | 0.42 (0.25–0.70) | 0.51 (0.33–0.79) | 0.42 (0.25–0.70) |

BRCA2 breast cancer 2, early onset gene, CI confidence interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio, PR progesterone receptor, TNM tumour, node, metastasis

Significant results are indicated by boldface type

*Analyses adjusted for country, age at diagnosis and calendar year of diagnosis

*Some data for each pathologic feature are not available
compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage \((P\) for trend \(= 2.14 \times 10^{-5}\)) and higher grade \((P\) for trend \(= 0.005\)), presented more frequently with lymph node involvement (OR 1.55, 95 % CI 1.12–2.14) and were more likely to be ER+ (OR 10.59, 95 % CI 5.15–21.80), PR+ (OR 5.04; 95 % CI 3.17–8.04) and non–triple-negative (OR 0.05, 95 % CI 0.01–0.22). Associations with stage and nodal, ER and PR status remained significant after adjustment for grade.

We then compared pathologic features of MBC arising in BRCA2 mutation carriers with characteristics of MBC in the general U.S. population as represented by SEER. We extracted pathology data of 6351 men with invasive breast cancer from the SEER 18 database. There were no statistically significant differences in pathology characteristics between MBCs arising in BRCA2 mutation carriers and those arising in the general population, with the exception of grade and lymph node status (Table 2).

### Table 2 Pathology of invasive MBCs in the general population from SEER and BRCA2 MBCs and ORs in predicting male BRCA2 mutation carrier status

<table>
<thead>
<tr>
<th></th>
<th>SEER Number</th>
<th>SEER Percent</th>
<th>BRCA2 carriers Number</th>
<th>BRCA2 carriers Percent</th>
<th>Unadjusted OR (95 % CI)</th>
<th>Adjusted OR(^a) (95 % CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total(^b)</strong></td>
<td>6351</td>
<td>326</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Morphology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ductal carcinoma</td>
<td>5265</td>
<td>86.2</td>
<td>253</td>
<td>95.1</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Lobular carcinoma</td>
<td>82</td>
<td>1.5</td>
<td>4</td>
<td>1.5</td>
<td>1.02 (0.37–2.79)</td>
<td>1.00 (0.36–2.74)</td>
</tr>
<tr>
<td>Medullary Carcinoma</td>
<td>16</td>
<td>0.3</td>
<td>2</td>
<td>0.8</td>
<td>2.60 (0.59–11.38)</td>
<td>2.34 (0.52–10.39)</td>
</tr>
<tr>
<td><strong>TNM stage</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–1</td>
<td>1699</td>
<td>34.9</td>
<td>44</td>
<td>29.5</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>2</td>
<td>1990</td>
<td>40.9</td>
<td>70</td>
<td>47.0</td>
<td>1.36 (0.93–1.99)</td>
<td>1.37 (0.93–2.01)</td>
</tr>
<tr>
<td>3–4</td>
<td>1181</td>
<td>24.2</td>
<td>35</td>
<td>23.5</td>
<td>1.14 (0.73–1.77)</td>
<td>1.11 (0.72–1.73)</td>
</tr>
<tr>
<td><strong>Histologic grade</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1</td>
<td>632</td>
<td>12.9</td>
<td>8</td>
<td>3.5</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Grade 2</td>
<td>2432</td>
<td>49.7</td>
<td>92</td>
<td>39.8</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Grade 3</td>
<td>1834</td>
<td>37.4</td>
<td>131</td>
<td>56.7</td>
<td>5.64 (2.75–11.60)</td>
<td>5.53 (2.69–11.39)</td>
</tr>
<tr>
<td><strong>Lymph node status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>2773</td>
<td>58.0</td>
<td>123</td>
<td>50.2</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Positive</td>
<td>2009</td>
<td>42.0</td>
<td>122</td>
<td>49.8</td>
<td>1.37 (1.05–1.78)</td>
<td>1.28 (0.98–1.67)</td>
</tr>
<tr>
<td><strong>ER status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>229</td>
<td>5.3</td>
<td>8</td>
<td>3.3</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Positive</td>
<td>4064</td>
<td>94.7</td>
<td>236</td>
<td>96.7</td>
<td>1.66 (0.81–3.41)</td>
<td>1.95 (0.93–4.06)</td>
</tr>
<tr>
<td><strong>PR status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>627</td>
<td>15.0</td>
<td>30</td>
<td>13.2</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Positive</td>
<td>3562</td>
<td>85.0</td>
<td>198</td>
<td>86.8</td>
<td>1.16 (0.79–1.72)</td>
<td>1.30 (0.88–1.92)</td>
</tr>
<tr>
<td><strong>HER2 status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>627</td>
<td>87.8</td>
<td>126</td>
<td>83.4</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Positive</td>
<td>87</td>
<td>12.2</td>
<td>25</td>
<td>16.6</td>
<td>1.43 (0.88–2.32)</td>
<td>1.30 (0.79–2.13)</td>
</tr>
<tr>
<td><strong>Subtypes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER+ and/or PR+, HER2−</td>
<td>608</td>
<td>87.5</td>
<td>118</td>
<td>81.9</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>ER+ and/or PR+, HER2+</td>
<td>80</td>
<td>11.5</td>
<td>22</td>
<td>15.3</td>
<td>1.42 (0.85–2.36)</td>
<td>1.28 (0.76–2.17)</td>
</tr>
<tr>
<td>ER−, PR−, HER2+</td>
<td>7</td>
<td>1.0</td>
<td>2</td>
<td>1.4</td>
<td>1.47 (0.30–7.18)</td>
<td>1.09 (0.22–5.45)</td>
</tr>
<tr>
<td>Triple-negative (ER−, PR−, HER2−)</td>
<td>0</td>
<td>0.0</td>
<td>2</td>
<td>1.4</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>ER+ and/or PR+, HER2− vs. others</td>
<td>1.54 (0.95–2.49)</td>
<td>1.38 (0.84–2.27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BRCA2 breast cancer 2, early onset gene, CI confidence interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio, PR progesterone receptor, TNM tumour, node, metastasis

Significant results are indicated by boldface type

\(^a\)Analyses adjusted for age at diagnosis and calendar year of diagnosis

\(^b\)Some data for each pathologic feature are not available
Male *BRCA2* mutation carriers more frequently had grades 2 and 3 tumours than grade 1 tumours, as compared with MBC cases from the general population (grade 2 vs. grade 1 OR 2.98, 95% CI 1.44–6.19; grade 3 vs. grade 1 OR 5.53, 95% CI 2.69–11.39; \( P \) for trend = 4.52 × 10^{-12}). Moreover, *BRCA2* mutation carriers presented more frequently with lymph node involvement than MBC cases from the general population, a difference that was not significant when adjusted for age at diagnosis and/or grade.

**Characterisation of *BRCA1* MBCs: comparison with *BRCA1* FBC and with MBC in the general population**

A total of 5925 country-matched female *BRCA1* mutation carriers diagnosed with invasive breast cancer were compared with our *BRCA1* MBC series, which revealed that MBCs were of significantly higher stage (stage 3–4 vs. stage 1 OR 17.59, 95% CI 3.47–89.03; \( P \) for trend = 0.001) and presented more frequently with lymph node involvement (OR 2.19, 95% CI 1.03–4.65) than FBCs in *BRCA1* mutation carriers (Additional file 5). The association with stage remained significant after adjusting for ER and PR status. Moreover, *BRCA1* MBCs were more likely to be ER+ (OR 20.22, 95% CI 5.91–69.17), PR+ (OR 13.76, 95% CI 5.31–35.67) and non–triple-negative (OR 0.03, 95% CI 0.00–0.25). The associations with ER and PR status remained significant after adjustment for stage. There was no statistically significant difference in the distribution of histologic grade among male and female *BRCA1* breast cancers.

The comparison between MBCs arising in *BRCA1* mutation carriers with those of 6351 MBCs from the SEER database showed no significant differences in pathologic characteristics (Additional file 6). However, *BRCA1* male breast tumours trended toward higher grade compared with those in the general population (\( P \) for trend = 0.003).

**Discussion**

To date, most of the available knowledge on MBC is based on MBC arising in the general population, whose *BRCA1* mutation status is largely unknown. In this study, we sought to determine whether MBC arising in *BRCA1* and *BRCA2* mutation carriers displayed specific pathologic characteristics. We used data on 419 MBCs with *BRCA1* and *BRCA2* mutations from an international consortium (CIMBA). The CIMBA series represents the largest collection of MBCs arising in *BRCA1* and *BRCA2* mutation carriers to date. In our series, the majority of MBC cases (375 of 419, 89.5%) were *BRCA2* mutation carriers, a finding which corroborates prior, smaller studies.

In this study, we conducted the first comparison of the pathologic features of breast cancer arising in male and female *BRCA1* mutation carriers, taking advantage of the previously collected pathology data from female *BRCA1* mutation carriers assembled by CIMBA [13].

We found that breast cancer in male *BRCA2* mutation carriers was of significantly higher stage and histologic grade, and was more frequently ER+ and PR+, than breast cancer in female *BRCA2* mutation carriers. Advanced stage disease at breast cancer diagnosis is more frequently observed in men than in women [23]. In general, this is thought to reflect diagnostic delay in a population unaware of its risk and (appropriately) not encouraged to undergo routine breast cancer screening. Furthermore, although breast cancer primaries in men tend to be slightly smaller than those in women when they are first diagnosed, they more often have locoregional metastasis at presentation. Indeed, we found that male *BRCA2* mutation carriers presented more frequently with lymph node involvement than breast cancer in female mutation carriers.

It is known that MBC presents with lower histologic grade tumours than FBC in the general population [11]. In contrast, in the present study, we showed that MBC associated with *BRCA2* mutations presents with higher histologic grade than both breast cancer in female *BRCA2* mutation carriers and MBC in the general population from SEER.

We observed that the majority of *BRCA2* MBCs are of grades 2 and 3. However, grade 3 tumours were more frequent among male *BRCA2* mutation carriers diagnosed at younger ages (younger than age 50 years) than among those diagnosed at older ages, whereas grade 2 tumours showed an inverse trend. Age-specific proportions of MBCs stratified by grade show that grade 3 significantly decreased with increasing age in male *BRCA2* mutation carriers. These results may indicate that young male *BRCA2* mutation carriers could be susceptible to more aggressive (i.e., high-grade) breast cancer. Differences in grade among male breast carcinomas by age may be an indicator of a biologic complexity in MBC, as suggested in FBC [24].

In a previous, single-country case series, MBCs associated with *BRCA2* mutations were found to be of higher grade than non-*BRCA2* MBC [16]. In the present study, we confirmed this association in a large, multicentre series and showed that this association was age-specific. The identification of a specific *BRCA2*-associated phenotype suggestive of an aggressive behaviour might define a subset of MBC patients (i.e., patients with high-grade breast tumours and with young age at diagnosis) who may particularly benefit from adjuvant chemotherapy [2, 25].

We also showed that high-grade breast tumours were more likely to arise in male than in female *BRCA2* mutation carriers, indicating that *BRCA2* mutations might be associated with different breast cancer phenotypes in men and in women. It has been suggested that high grade is a surrogate for proliferation, and although the evidence is conflicting, this may add to the understanding of the molecular differences of MBC and FBC.
MBC is recognised as being primarily a hormone-dependent malignancy, and, in general, MBC is described as being more frequently ER+ and PR+ than FBC [10, 11, 23]. In the present study, we showed that BRCA2 MBCs are more likely than BRCA2 FBCs to be ER+ and PR+, thus suggesting that susceptibility to hereditary breast cancer may be influenced by differences in hormonal background between male and female BRCA2 mutation carriers.

Invasive lobular carcinomas are very rare in men, accounting for only about 2% of all MBCs [23, 26]. We also found significantly fewer lobular carcinomas among male than female BRCA2 mutation carriers. However, it is worth noting that breast cancers in female BRCA2 mutation carriers frequently show a lobular morphology [13], thus suggesting differences in the pathogenic mechanisms of male and female BRCA2 breast cancer.

The number of MBC cases with BRCA1 mutations in our datasets was much smaller than the number of BRCA2 mutation carriers, and our results in this subset of patients should therefore be interpreted with caution. We found that BRCA1 MBC cases were of significantly higher stage, and more frequently ER+ and PR+, than BRCA1 FBCs. Despite the small sample size, our results suggest that hormone receptor pathways also are a driving force in BRCA1 MBC. It is well known that most of the breast tumours arising in female BRCA1 mutation carriers tend to be ER− and PR−, with a small percentage being ER+ [13, 27, 28]. Given that both ER− and ER+ BRCA1 breast cancers seem to originate from a common luminal progenitor cell population, it has been suggested that ER status of breast cancer occurring in BRCA1 mutation carriers may be under control of different molecular mechanisms [29]. The finding that MBCs associated with BRCA1 mutations are frequently ER+ suggests that the hormonal milieu may be a mechanism controlling ER status in BRCA1 tumours. The different hormonal background between males and females and the absence of hormone exposures related to reproductive history in males as compared with FBC may also influence biologic and molecular mechanisms underlying the pathologic differences between MBC and FBC. Following the findings in the present study, future studies are warranted which focus on the comprehensive somatic and molecular profiling of MBC and FBC in mutation carriers. Such studies could provide new insights into the complex nature of the origin and evolution of MBC and FBC.

Interestingly, we found no statistically significant differences in the pathologic characteristics between MBCs in BRCA1/2 mutation carriers and those in the general population, with the exception of histologic grade. Male BRCA2 mutation carriers more frequently have grade 2/3 vs. grade 1 tumours, compared with the large, unselected population of MBC cases from SEER. A similar trend also was observed for BRCA1 mutation carriers. These findings suggest that, although MBCs arising in male BRCA1/2 mutation carriers seem to be very similar to MBCs arising in the general population, according to morphologic and immunophenotypic features, they represent a subgroup characterised by aggressive biology.

The importance of histologic grade as a prognostic factor in breast cancer has been ascertained in FBC [30]. Recent data indicate that high-grade tumours are associated with shorter disease-free survival and overall survival rates in MBC patients [25]. Thus, on the basis of our results, we can suggest that BRCA2 MBC may display an aggressive phenotype and possibly a more unfavourable prognosis. This is a question in need of additional survival data that we are planning to collect within CIMBA.

In this study, tumour pathology data were collected through several mechanisms, including medical records, pathology reports and TMAs. Given the global distribution of CIMBA study sites, central pathology review was not feasible. Laboratory methods for tissue preparation, IHC, biochemical assays, scoring systems and data interpretation vary widely (Additional file 3), and misclassifications cannot be excluded. Unfortunately, details of hormone receptor scoring for all mutation carriers were not available to standardise definitions across centres. However, data collected by CIMBA are more representative of typical assessment of pathology conducted in routine practice, and the distributions of hormone receptors’ status across different study centres and countries in CIMBA were generally consistent. There was some variation in the distribution of some variables, including ER status, probably due to changing assay thresholds and detection methods over time and from country to country. Therefore, adjustments based on calendar year of diagnosis and country of origin were included for all analyses. Missing data for some variables, including HER2 status, and the very small number of male BRCA1 mutation carriers in the study may have impacted the statistical power to detect associations.

CIMBA collects data only on BRCA1 and BRCA2 mutation carriers. Therefore, to compare the tumour characteristics of MBC from the general population, we took advantage of the publicly available SEER data [20]. Although the U.S. SEER program is the largest source of epidemiologic information on the incidence and survival rates of cancer, it includes data from a single country, and this represents a limitation when attempting to generalise our findings to what one would expect in a collaborative international consortium. However, results from this study, based on a large, multicentre series, replicated previous findings of much smaller studies carried out in single populations [14–17], providing some reassurance that our results were not biased by the different selection of cases in SEER and in CIMBA. In addition, SEER includes MBCs that were not screened for BRCA1 and BRCA2 mutations, and it can be expected that about...
10% of those cases [3, 21, 22] may be due to BRCA1 or BRCA2 mutations. In future studies, researchers should aim to compare BRCA1/2 MBC cases with those known not to have BRCA1/2 mutations.

Conclusions

Analysing the largest series of BRCA1 and BRCA2 breast cancers collected to date from both sexes, we have demonstrated that breast tumours arising in BRCA1 and BRCA2 mutation carriers display pathologic differences between males and females. Thus, our results add to the accumulating evidence that breast cancer may not be the same disease in both genders [12] and suggest that the heritable influence on breast cancer susceptibility may be context-dependent, perhaps influenced by the microenvironment (i.e., a different hormonal milieu in males and females).

Moreover, we identified a specific BRCA2-associated MBC phenotype characterised by higher histologic grade compared with both BRCA2 FBC and MBC from a general population. This raises the possibility that BRCA2 MBC may be more aggressive than its sporadic counterpart.

Overall, our findings could lead to the eventual development of clinical strategies appropriate for MBC management, and of gender-specific risk prediction models that might guide more targeted screening and surveillance programs for male mutation carriers.

Additional files

Additional file 1: Male BRCA1 and BRCA2 mutation carriers by study group/country. (DOCX 21 kb)

Additional file 2: List of local ethics committees that granted approval for the access and use of the data in present study. (DOCX 23 kb)

Additional file 3: Methods and thresholds used to define the final marker variables for study groups providing MBC cases. (DOCX 20 kb)

Additional file 4: Pathology of BRCA1 and BRCA2 MBCs and ORs in predicting BRCA2 mutation carrier status. (DOCX 20 kb)

Additional file 5: Pathology of invasive BRCA1 female and male breast tumours and ORs in predicting male BRCA1 mutation carrier status. (DOCX 19 kb)

Additional file 6: Pathology of invasive MBCs in the general population from SEER and BRCA1 MBCs and ORs in predicting male BRCA1 mutation carrier status. (DOCX 19 kb)

Abbreviations

BC: breast cancer; BRCA1: breast cancer 1, early onset gene; BRCA2: breast cancer 2, early onset gene; CI: confidence interval; CIMBA: Consortium of Investigators of Modifiers of BRCA1/2; ER: oestrogen receptor; FBC: female breast cancer; HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry; IQR: interquartile range; MBC: male breast cancer; OR: odds ratio; PR: progesterone receptor; SEER: Surveillance, Epidemiology, and End Results; TMA: tissue microarray; TNM: tumour, node, metastasis.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions


Acknowledgements

BFRC This work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BFCR), nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government or the BFRC. BFRC-AU: Acknowledge Maggie Agekianos, Judi Maskell, Gillian Dite and Helen Tsikiades. BFRC-NN: We thank members and participants in the New York site of the Breast Cancer Family Registry for their contributions to the study. BFRC-ON: We thank members and participants in the Ontario Familial Breast Cancer Registry for their contributions to the study. BFROCC-LT is partly supported by Research Council of Lithuania grant LIG-07/2012. We acknowledge Vilius Rudatis and Laimonas Grīškėvičius. BIDMC is supported by the Breast Cancer Research Foundation. BRICOH: SLN was partially supported by the Morris and Horowitz Families Endowed Professorship. CBS: This work was supported by the NEYE Foundation. CNO: This work was partially supported by Spanish Association against Cancer (AECOC08), RTICC 06/0020/1060, FIS/P08/1120, Mutua Madrileña Foundation (FMMA) and SAF2010-20493. We thank Alicia Barroso, Rosario Alonso and Guillermo Pita for their assistance. COH-CCGCRN: City of Hope Clinical Cancer Genetics Community Network and the Hereditary Cancer Research Registry, supported in part by award number RC4CA153828 (UNW, principal investigator) from the National Cancer Institute and the Office of the Director, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. CONSIT TEAM: Funds from Italian citizens who allocated the 5 x 1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (NT institutional strategic projects ‘5 x 1000’) to SM and from FossGen Foundation for Pharmacogenomics to LP. LO is supported by AIRC (IG12780). VS is supported by FIRC (triennial fellowship “Mario e Valeria Rindi”). We acknowledge Maria Grazia Tibletti of the Ospedale di Circolo-Università dell’Insubria, Varese, Italy. CORE: The CIMBA data management and data analysis were supported by Cancer Research UK grants C12292/11714 and C1287/1A1018. SH is supported by an NHMRC program grant (GCT). ACA is a Cancer Research UK senior cancer research fellow. GCT is an NHMRC senior principal research fellow. DEMOKRITOS: This research has been co-financed by the European Union (European Social Fund (ESF)) and Greek national funds through the Operational Program “Education and Lifelong Learning” of the National Strategic Reference Framework (NSRF) - Research Funding Program of the General Secretariat for Research & Technology: ARISTEIA. Investing in knowledge society through the European Social Fund. DFKZ: The DFKZ study was supported by the DFKZ. EMBRACE is supported by Cancer Research UK grants C1287/1A1018 and C1287/1A1090. DGE and Fiona Laloo are supported by an NIH grant to the Biomedical Research Centre, Manchester, UK. The investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIH grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE and Elizabet Bancroft are supported by Cancer Research UK grant CS047/AS385. RE is also supported by NIH support of the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE and Elizabet Bancroft are supported by Cancer Research UK grant CS047/AS385. RE is also supported by NIH support of the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIH support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIH support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIH support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIH support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIH support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIH support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIH support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIH support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIH support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIH support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIH support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant 110837 to Rita K. Schmutzler) and by the Center for Molecular Medicine Cologne (CMMC). GEMO: The study was supported by the Ligue Nationale contre le Cancer; the Association "Le cancer du sein, parons-en" Award; the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program and the French National Institute of Cancer (INCA). Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) study: National Cancer Genetics Network. "UNICANCER Genetic Group", France. We thank all the GEMO collaborating groups for their contribution to this study. GEMO Collaborating Centers are Coordinating Centers: Unité Mixte de Génétique Constitutive des Cancers Fréquents, Hospices Civils de Lyon - Centre Léon Bérard, & Equipe « Génétique du cancer du sein», Centre de Recherche en Cancérologie de Lyon: Olga Sinilnikova*, Sylvie Mazoyer, Francesca Damilopa, Laure Barjhoux, Caroline Venny-Pierre, Mélanie Leonce, Nadia Bouty-Kiya, Alain Calender, Sophie Giraud, and Service de Génétique Oncologique, Institut Curie, Paris: Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Claude Houdayer, Etienne Rouleau, Lisa Golmard, Agnès Collet, Virginie Moncoutier, Cédric Lefol, Muriel Berloti, Antoine de Pauw, Camille Elan, Catherine Noguès, Emmanuelle Fourme, Anne-Marie Broit. Institut Gustave Roussy, Villejuif: Brigitte Bressac-de-Paillerets, Olivier Caron, Marine Guillaud-Bataille. Centre Jean Perrin, Clermont-Ferrand: Yves-Jean Bignon, Nancy Uhrrhammer. Centre Léon Bérard, Lyon: Christine Lasser, Valérie Bonadonna, Sandrine Handallou. Centre François Baclesse, Caen: Agnès Hardouin, Pascaline Uhrhammer. Centre Léon Bérard, Lyon: Christine Lasset, Valérie Bonadonna, Sandrine Handallou. Centre François Baclesse, Caen: Agnès Hardouin, Pascaline Uhrhammer. Centre Arnaud-de-Villeneuve, Montpellier: Isabelle Coupelier, Pascal Pujo. Centre Oscar Lambret, Lille: Jean-Philippe Peyrat, Joëlle Fournier, Françoise Dreyfus, Christine Rebischung, Magalie Peysselon. CHU St-Etienne: Fabienne Prieur, Marine Lebrun, Caroline Kientz. Hôtel Dieu Centre Hospitalier, Charolcy: Sandra Fer Fener. Centre Antoine Lacassagne, Nice: Marc Fréniay. CHU Limoges: Laurence Vénat-Bouvet. CHU Nantes: Capucine Delatte. CHU Brestonneau, Tours: Isabelle Montemousse. Groupe Hospitalier Pitie-Salpêtrière, Paris: Florence Coulet, Christylene Colas, Florent Soubert, Mathilde Warco. CHU Vandoeuvre-les-Nancy: Johanna Sokolowska, Myriam Bronner. CHU Besançon: Marie-Agnès Collonge-Rame, Alexandre Damette. Creighton University, Omaha, NE, USA: Henry T. Lynch, Carrie L. Snyder, Georgetown University: CI received support from the Non-Therapeutic Subject Registry: Shared Resource at Georgetown University (NHGRI grant P30-CAUS1008), the Fisher Center for Familial Cancer Research, and for the Cure. G-FAST: Kim De Leeener is supported by GOA grant BOF10/GOA/019 (Ghent University) and spearheaded financing of Ghent University Hospital. We thank the technical support of Ilse Coene en Brecht Crombez. HCSC was supported by a grant RD12/00369/0006 and 12/00539 from ICGI (Spain), partially supported by European Regional Development FEDER funds. We acknowledge Alicia Tosar for her technical assistance. HBES was supported by the Helsinki University Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius Foundation. HBES thanks Taru A. Muananen, Drs. Carl Blomqvist and Krismiri Aaltosen and RNs Ilja Erkkilä and Virpi Palola for their help with the HBES data and samples. HEBON is supported by the Dutch Cancer Society grants NK9198-1854, NK0204-3088, NK0207-3756, the Netherlands Organization of Scientific Research grant NWO 91109024, the Pink Ribbon grant 110005 and the BBMRI grant NWO 184.021.007/C4P6. HEBON thanks the registration teams of the Comprehensive Cancer Centre Netherlands and Comprehensive Centre South (together the Netherlands Cancer Registry) and PALGA (Dutch Pathology Registry) for part of the data collection. The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) consists of the following collaborating centres: coordinating centre: Netherlands Cancer Institute, Amsterdam, the Netherlands: M. A. Rookus, F. B. L. Hogervorst, F. E. van Leeuwen, M. J. Blok; University Medical Center Utrecht, the Netherlands: M. G. E. M. Ausems, R. B. van der Luijt, C. C. van der Pol; Amsterdam Medical Center, Amsterdam, the Netherlands: C. M. Aals, T. A. M. van Os; VU University Medical Center, Amsterdam, Amsterdam, the Netherlands: J. J. P. Gille, Q. Waisfiz, H. E. J. Meijers-Heijboer; University Hospital Maastricht, the Netherlands: E. B. Gómez-Garcia, M. J. Blok; University Medical Center Groningen, the Netherlands: J. C. Oosterwijk, A. H. van der Hout, M. J. Mourtis, Gh. H. de Bock; The Netherlands Foundation for the detection of hereditary tumours, Leiden, the Netherlands: H. F. Van; The Netherlands Comprehensive Cancer Organization (IKNL); S. Siesling, J. Verloot, The Dutch Pathology Registry (PALGA) L. I. H. Overbeek. The HEBON study is supported by the Dutch Cancer Society grants NK9198-1854, NK0204-3088, NK0207-3756, the Netherlands Organization of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187-W076, the BBMRI grant NWO 184.021.007/C4P6 and the Transcan grant JTC 2012 Cancer 12-054. HEBON thanks the registration teams of IKNL and PALGA for part of the data collection. HRBCP is supported by The Hong Kong Hereditary Breast Cancer Family Registry and the Dr. Ellen Li Charitable Foundation, Hong Kong. We thank the Hong Kong Sanatorium and Hospital for their continual support. HUNBCOS: Breast and Ovarian Cancer Study was supported by Hungarian research grants KIA-OTKA CK-B80745, OTKA K 112228 and the Norwegian EEA Financial Mechanism Hu015/NA/2008-3/OP-9. We thank the Hungarian Breast and Ovarian Cancer Study Group members (Janos Papp, Tibor Vaszkó, Aniko Bozóki, Maria Falcoza, Judit Franko, Maria Balog, Gabriella Pujo, Judit Ferenczi, Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary) and the clinicians and patients for their contributions to this study. HtVH: We thank the Oncogenetics Group (VHIO), and the High Risk and Cancer Prevention Unit of the University Hospital Vall d’Hebron. ICO: Contract grant sponsor: Asociación Española Contra el Cáncer, Spanish Health Research Fund; Carlos III Health Institute; Catalán Health Institute and Autonomous Government of Catalunya. Contract grant numbers: ISCIII: RETIC RD06/0020/1051, RD12/0036/0008, PI1001/422, PI1007/0478, PI1300285, P131002002, 2009SGR290 and 2014SGR304. We thank the IICO Hereditary Cancer Program team led by Dr. Gabriel Capella. The IHCC was supported by grant PBZ_RBN_122/P04/2005. The ILUH group was supported by the Icelandic Association "Walking for Breast Cancer Research" and by the Landspítali University Hospital Research Fund. IOV+HBCS is supported by Ministerio della Salute and "5 x 1000" Istituto Oncologico Veneto grant. IPOBCS: This study was in part supported by Liga Portuguesa Contra o Cancro. We thank Drs. Ana Peixoto, Catarina Santos, Patricia Rocha and Pedro Pinto for their skilful contribution to the study. KcOnFab is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC). The Queensland Cancer Fund, the Cancer Council of New South Wales, the Tasmanian and South Australian Cancer Foundation of Western Australia; We thank Heather Thorne, Eveline Niedermayr, all the KcOnFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (which has received funding from the NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the National Institutes of Health (USA)) for their contributions to this resource, and the many families who contribute to KcOnFab. KcOnFab is supported by a grant from the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea (1020350). MAYO is supported by NIH grants CA116167, CA128978 and CA176785, an unrestricted gift from the David F. and Margaret T. Grohe Family Foundation and the Ting Tsai and Weng Fong Chao Foundation. MOdOSQUAD was supported by MH CZ - DRO (MOCI_00209805) and by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/03.01.01/01.01.00/03.01/001 to LF, and by Charles University in Prague project UNCE204024 (to M2). MOdOSQUAD acknowledges ModOSQUAD members: Csilla Szabó (National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA) and Michal Zíkan, Petr Kofohl and Zdeněk Neből (Oncogenetics Center and Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic). MSKCC is supported by grants from the Breast Cancer Research Foundation, the Robert and Kate Niehaus Clinical Cancer Genetics Initiative, and the Andrew Sabin Research Fund. NCI: The research of NIH and PLM was supported by the Intramural Research Program.
of the National Cancer Institute, NIH, and by support services contracts NO2-CP-11019-50 and NO2-CP-65504 with Westat, Inc., Rockville, MD, USA.

NPIOP: This work has been supported by the Russian Federation for Basic Research (grants 13-04-92613, 14-04-93959 and 15-04-01744). OCGN: We thank members and participants in the Ontario Cancer Genetics Network for their contributions to the study. OSUCCG is supported by The Ohio State University Comprehensive Cancer Center. Leigha Senter, Kevin Sweet, Caroline Craven and Michelle O'Connor were instrumental in accrual of study participants, ascertainment of medical records and database management. Samples were processed by the OSU Human Genomics Sample Bank. PBCS: This work was supported by the IIT (Istituto Toscano Tumori) grants 2011–2013.

SEABASS: Ministry of Science, Technology and Innovation, Ministry of Higher Education (UMC/HR/MOHE/06) and Cancer Research Initiatives Foundation. We thank Yip Cheng Har, Nur Aishah Mohd Taib, Phuah Sze Yee, Norhashimah Hassan and all the research nurses, research assistants and doctors involved in the MyBRca Study for assistance in patient recruitment, data collection and sample preparation. In addition, we thank Philip Iau, Sng Jen-Hwee and Shanfah Nor Akmal for contributing samples from the Singapore Breast Cancer Study and the HUKOA-HKL Study, respectively. The Malaysian Breast Cancer Genetic Study is funded by research grants from the Malaysian Ministry of Science, Technology and Innovation, Ministry of Higher Education (UMC/HR/MOHE/06) and charitable funding from Cancer Research Initiatives Foundation. SWE-BRCA collaborators are supported by the Swedish Cancer Society. Swedish scientists participating as SWE-BRCA collaborators are as follows: from Lund University and University Hospital: Åke Borg, Hilkan Olsson, Helena Jernström, Karin Henriksson, Katja Harbst, Marika Giselsson, Ulf Edwinsdotter; from Gothenburg Sahlgrenska University Hospital: Anna Överholm, Margareta Nordling, Per Karlsson, Zakiya Einbeig; from Stockholm and Karolinska University Hospital: Anna von Wachenfeldt, Annelie Liljegren, Annika Lindblom, Brita Arver, Gisela Barbany Bustinza, Johanna Rantalä; from Umeå University Hospital: Beatrice Melin, Christina Edwinsdotter Arndt, Monica Emanuelsson; from Uppsala University: Hans Ehrencrona, Marittha Hellström Pigg, Richard Rosenquist; from Linköping University Hospital: Marie Stenmark-Aksam, Sigurd Lindgren. The University of Chicago is supported by NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA125183), R01 CA142996, 1U01CA161032 and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund Foundation National Women’s Cancer Research Alliance and the Breast Cancer Research Foundation. OIO is an American Cancer Society clinical research professor. We thank the following genetic counsellors for participant recruitment: Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Bianco and Peggy Conrad. Thanks are also extended to Ms. Salina Chan for her data management. UKFCR was supported by a grant from CRUK to Paul Pharoah. We thank Paul Pharoah, Simon Gayther, Susan Ramus, Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund Foundation (OIO) is an American Cancer Society clinical research professor. We thank the following genetic counsellors for participant recruitment: Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Bianco and Peggy Conrad. Thanks are also extended to Ms. Salina Chan for her data management. UKFCR was supported by a grant from CRUK to Paul Pharoah. We thank Paul Pharoah, Simon Gayther, Susan Ramus, Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund Foundation. OIO is an American Cancer Society clinical research professor. We thank the following genetic counsellors for participant recruitment: Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Bianco and Peggy Conrad. Thanks are also extended to Ms. Salina Chan for her data management. UKFCR was supported by a grant from CRUK to Paul Pharoah. We thank Paul Pharoah, Simon Gayther, Susan Ramus, Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund Foundation.

Page 11 of 13

Author details
1Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy.
2Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
3Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
4Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
5Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.
6Peter MacCallum Cancer Institute, East Melbourne, Australia.
7Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
8Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia.
9Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
10University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
11UPMC Cancer Center, Pittsburgh, PA, USA.
12Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA.
13Department of Epidemiology and Biostatistics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
14Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
15Department of Medicine and Genetics, University of California, San Francisco, San Francisco, CA, USA.
16Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, IL, USA.
17Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
18Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia.
19University Malaya Cancer Research Institute, Faculty of Medicine, University Malaya Medical Centre, University Malaya, Kuala Lumpur, Malaysia.
20Section of Genetic Oncology, Department of Laboratory Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy.
21Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark.
22Section of Molecular Diagnostics, Department of Biochemistry, Aalborg University Hospital, Aalborg, Denmark.
23Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark.
24Department of Clinical Genetics, Aarhus University Hospital, Aarhus N, Denmark.
25Department of Molecular Virology, Immunology and Medical Genetics, College of Medicine, The Ohio State University, Columbus, OH, USA.
26Division of Human Genetics, Department of Internal Medicine, The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
27Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
28Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
29Center for Medical Genetics, North Shore University Health System, Evanston, IL, USA.
30N.I. Petrov Institute of Oncology, St. Petersburg, Russia.
31Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
32Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
33Department of Urology, Medical University of Vienna, Vienna, Austria.
34Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
35Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
36Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
37Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
38Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
39Department of Hematology and Oncology, University of Rochester Medical Center, Rochester, MN, USA.
40Department of Oncology, Mayo Clinic, Rochester, MN, USA.
41Department of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA.
42Department of Surgery, Daerim St. Mary’s Hospital, Seoul, Korea.
43Department of Genetics, Portuguese Institute of Oncology, Porto, Portugal.
44Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
45Immunology and Molecular Oncology Unit, Veneto Institute of Oncology–IRCCS ‘Pasquale Catanese’ (ISICR; Section of Hospitalization and Care), Padua, Italy.
46Department of Pathology, Landspitali University Hospital and Biomedical Centre (BMC), Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
47Department of Oncology, Landspitali University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
48Department of Genetics and Pathology, Pomeranian
BRCA2

The Hong Kong Hereditary Breast Cancer Family Registry, Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong, China.

56. Department of Surgery, The University of Hong Kong, Hong Kong, China.

57. Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

58. Department of Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

59. Department of Oncology, San Carlos Clinical Hospital Health Research Institute (IDISSC), San Carlos Clinical Hospital, Madrid, Spain.

60. Molecular Oncology, Laboratory, San Carlos Clinical Hospital Health Research Institute (IDISSC), San Carlos Clinical Hospital, Madrid, Spain.

61. Center for Medical Genetics, Ghent University, Ghent, Belgium.

62. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.

63. Department of Tumour Biology, Institut Curie, Paris, France.

64. CNRS UMR5558, Université Lyon 1, Lyon, France.

65. Unité de Prévention et d’Epidémiologie Génétique, Centre Léon Bérard, Lyon, France.

66. Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

67. INSERM U1052, CNRS UMR2286, Centre de Recherche en Cancérologie de Lyon, Université Lyon, Lyon, France.

68. Department of Gynaecology and Obstetrics, Technical University of Munich, Munich, Germany.

69. Institute of Human Genetics, University of Wurzburg, Wurzburg, Germany.

70. Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany.

71. Institute for Medical Informatics, Statistics and Epidemiology University of Leipzig, Leipzig, Germany.

72. University of Dusseldorf, Dusseldorf, Germany.

73. Hannover Medical School, Hannover, Germany.

74. Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.

75. Department of Gynecology and Obstetrics, Technical University of Dresden, Dresden, Germany.

76. Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany.

77. Institute of Human Genetics, Charité, Berlin, Germany.

78. Institute of Human Genetics, Leipzig, Germany.

79. Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.

80. Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.

81. Yorkshire Regional Genetics Service, Leeds, UK.

82. Clinical Genetics, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK.

83. Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.

84. Molecular Genetics of Breast Cancer, German Cancer Research Center (DFKZ), Heidelberg, Germany.

85. Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, MA, USA.

86. Molecular Diagnostics Laboratory, Institute of Nuclear and Radiological Sciences and Technology (INRATES), National Centre for Scientific Research “Demokritos”, Aghia Paraskevi Attikis, Athens, Greece.

87. Department of Medical Oncology, Papageorgiou Hospital, Aristotel University of Thessaloniki School of Medicine, Thessaloniki, Greece.

88. Department of Medical Science, University of Turin, Turin, Italy.

89. AO Città della Salute e della Scienza, Turin, Italy.

90. Section of Medical Oncology, Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy.

91. Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy.

92. Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.

93. Unit of Hereditary Cancer, Department of Epidemiology, Prevention and Special Functions, IRCCS (Scientific Institute of Hospitalization and Care), AOU San Martino - IST National Institute for Cancer Research, Genoa, Italy.

94. Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy.

95. Unit of Genetic Counselling, Medical Oncology Department, Regina Elena National Cancer Institute, Rome, Italy.

96. Unit of Molecular Basis of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, IRCCS (Scientific Institute of Hospitalization and Care), National Cancer Institute (INT), 20133 Milan, Italy.

97. Department of Preventive and Predictive Medicine, IRCCS (Scientific Institute of Hospitalization and Care), National Cancer Institute (INT), Milan, Italy.

98. Division of Cancer Prevention and Genetics, European Institute of Oncology (IEO), Milan, Italy.

99. Division of Experimental Oncology, CRO Aviano National Cancer Institute, Aviano, PN, Italy.

100. IFOM, IRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy.

101. Cogentech Cancer Genetic Test Laboratory, Milan, Italy.

102. National Cancer Institute “Giovanni Paolo II”, Bari, Italy.

103. Clinical Cancer Genetics, City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA.

104. Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Centre (CNIO), Madrid, Spain.

105. Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.

106. Human Genotyping (CEGEN) Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

107. Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia.

108. Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

109. Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

110. Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

111. Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

112. State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.

113. Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Centre Léon Bérard, Lyon, France.

114. Department of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.

115. Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.

116. Department of Pathology & Molecular Medicine, Javrais Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada.

117. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.

118. Department of Epidemiology, Cancer Prevention Institute of California, Freemont, CA, USA.

119. Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Parkville, Australia.

Received: 28 September 2015 Accepted: 6 January 2016

Published online: 09 February 2016

References


